Compare Abbott Laboratories (ABT) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.79. The key difference: Abbott Laboratories pays a 2.63% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | FLRN | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $136.62 | $30.86 |
52-Week Low | $82.57 | $30.65 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.78, showing minimal daily movement with a 0.07% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights institutional buying interest amid a higher-for-longer interest rate environment, positioning FLRN as a potential hedge against inflation. The ETF pays consistent dividends, with recent distributions of $0.11 per share.
The outlook for FLRN is cautiously positive, benefiting from its floating-rate structure in a rising rate climate. Key opportunities include inflation protection and steady income, while risks involve interest rate volatility and economic shifts that could impact credit quality. Investor sentiment is mixed, with technical signals leaning bearish but fundamental appeal in current macro conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
